MTHFR and Ehlers-Danlos Syndrome

MTHFR and Ehlers-Danlos Syndrome

Introduction

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by joint hypermobility, tissue fragility, and a broad spectrum of systemic symptoms. Despite its prevalence, hEDS remains poorly understood, with no definitive genetic marker identified. Recent studies suggest that genetic mutations in the methylenetetrahydrofolate reductase (MTHFR) gene may play a role in the condition's pathophysiology, providing new insights into its mechanisms and potential therapeutic approaches.

MTHFR and Folate Metabolism

MTHFR is an essential enzyme that converts folate (vitamin B9) into its active form, 5-methyltetrahydrofolate (5-MTHF). This active form supports DNA synthesis, amino acid metabolism, and methylation processes critical for cellular function. Two common polymorphisms in the MTHFR gene, C677T and A1298C, reduce enzyme activity, leading to elevated levels of unmetabolized folate and disrupted biological pathways.

Evidence Linking MTHFR to hEDS

Recent research has revealed a potential connection between MTHFR polymorphisms and hEDS. A study conducted at the Tulane Fascia Institute reported a high prevalence of MTHFR polymorphisms among patients with hEDS and hypermobility spectrum disorders (HSD). Approximately 85% of patients exhibited at least one MTHFR polymorphism, and 41.4% carried two variants (heterozygous or homozygous) that significantly impair enzyme activity. This impaired activity leads to a cascade of biochemical disruptions, notably affecting the extracellular matrix (ECM).

The enzyme matrix metalloproteinase-2 (MMP-2) becomes hyperactive in the absence of sufficient 5-MTHF, degrading decorin, a key structural protein in the ECM. This degradation weakens connective tissues, contributing to the joint instability and hypermobility characteristic of hEDS.

Therapeutic Implications: The Role of Methylfolate

Supplementing with methylfolate (5-MTHF) bypasses the enzymatic block caused by MTHFR polymorphisms, ensuring adequate active folate levels in the body. Early observations indicate that methylfolate supplementation could stabilize the ECM and potentially alleviate symptoms of hypermobility. This intervention is particularly promising because it is non-invasive, widely accessible, and generally safe.

Limitations and Contrasting Perspectives

While the correlation between MTHFR polymorphisms and hEDS is compelling, the causative role of these genetic variants is not universally accepted. Some large-scale genetic studies have failed to find a statistically significant association between MTHFR variants and hEDS, suggesting that other genetic or environmental factors may contribute to the condition. These findings highlight the need for further research to validate the proposed mechanisms and identify additional therapeutic targets.

Conclusion

The connection between MTHFR polymorphisms and hEDS represents an exciting frontier in understanding this complex disorder. Although the evidence is still emerging, the potential for methylfolate supplementation as a targeted treatment offers hope for patients. Continued research into the genetic and biochemical pathways of hEDS will be critical for refining diagnostic criteria and improving management strategies.

References

1. Courseault, J., Umar, M., Bordnick, P., Simons, J., Volic, M., Stock, A., & Bix, G. (2024). Prevalence of MTHFR Polymorphisms in Patients With Hypermobile Ehlers-Danlos Syndrome and Hypermobile Spectrum Disorders in a US Hypermobility Clinic. ACR open rheumatology, 6(7), 399–402. https://doi.org/10.1002/acr2.11667
2. Harris, D. "Norris Lab Researchers Discover Hypermobile EDS Gene." Ehlers-Danlos Syndrome (EDS), updated September 2024. The EDS Clinic. https://www.eds.clinic/articles/norris-lab-researchers-discover-hypermobile-eds-gene.
3. Gensemer, C., Beck, T., Guo, L., Petrucci, T., Morningstar, J., Kornblau, I., Byerly, K., Biggs, R., Weintraub, A., Moore, K., Koren, N., Daylor, V., Hastings, C., Oberlies, E., Zientara, E. R., Devey, E., Dooley, S., Stayer, K., Fenner, R., Singleton, K., … Norris, R. A. (2024). Variants in the Kallikrein Gene Family and Hypermobile Ehlers-Danlos Syndrome. Research square, rs.3.rs-4547888. https://doi.org/10.21203/rs.3.rs-4547888/v1
4. Courseault, J., Kingry, C., Morrison, V., Edstrom, C., Morrell, K., Jaubert, L., Elia, V., & Bix, G. (2023). Folate-dependent hypermobility syndrome: A proposed mechanism and diagnosis. Heliyon, 9(4), e15387. https://doi.org/10.1016/j.heliyon.2023.e15387

‍